Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.
Weiss, Glen J
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. [electronic resource] - Investigational new drugs Dec 2012 - 2334-43 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study
1573-0646
10.1007/s10637-011-9774-6 doi
Adolescent
Adult
Aged
Cyclin-Dependent Kinases--antagonists & inhibitors
Drug Administration Schedule
Female
Humans
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms--drug therapy
Protein Kinase Inhibitors--administration & dosage
Pyrazoles--administration & dosage
Quinazolines--administration & dosage
Receptor, trkA--antagonists & inhibitors
Treatment Outcome
Young Adult
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. [electronic resource] - Investigational new drugs Dec 2012 - 2334-43 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study
1573-0646
10.1007/s10637-011-9774-6 doi
Adolescent
Adult
Aged
Cyclin-Dependent Kinases--antagonists & inhibitors
Drug Administration Schedule
Female
Humans
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms--drug therapy
Protein Kinase Inhibitors--administration & dosage
Pyrazoles--administration & dosage
Quinazolines--administration & dosage
Receptor, trkA--antagonists & inhibitors
Treatment Outcome
Young Adult